Procaps Group S.A. (NASDAQ:PROC) Sees Large Decrease in Short Interest

Procaps Group S.A. (NASDAQ:PROCGet Free Report) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 163,300 shares, a decrease of 21.7% from the November 30th total of 208,500 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 96,000 shares, the short-interest ratio is presently 1.7 days.

Procaps Group Stock Performance

Shares of NASDAQ PROC opened at $2.28 on Tuesday. Procaps Group has a fifty-two week low of $0.50 and a fifty-two week high of $4.95. The company has a market cap of $257.23 million, a price-to-earnings ratio of 4.38 and a beta of 0.10. The business’s 50 day moving average price is $1.82 and its 200-day moving average price is $2.06.

About Procaps Group

(Get Free Report)

Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.

Read More

Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.